ILCN.org (ILCN/WCLC) ILCN.org (ILCN/WCLC)
twitter youtube facebook linkedin iaslc Home
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
Menu
  • Home
  • Featured Topics
    • Diagnostic Oncology
      • Early Detection & Screening
      • Evolving Standards of Care
      • Global Initiatives
    • Meeting News
      • Names & News
      • Nursing & Allied Health
      • Patient Advocacy
    • Radiation Oncology
      • Regulatory News
      • Risk Assessment and Reduction
      • Society News
    • Supportive & Palliative Care
      • Surgical Oncology
      • Tobacco & Smoking Cessation
      • WCLC News
  • WCLC News
  • About Us
loading...
Home Immuno-Biology

TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC

Beth Fand Incollingo
on: January 27, 2021In: Immuno-Biology
TKI Plus Checkpoint Inhibitor Without Chemotherapy Shows Promise as Initial Option in Advanced NSCLC

The combination of an anti-angiogenic tyrosine kinase inhibitor (TKI) and an anti-PD-1 immunotherapy proved promising, regardless of PD-L1 expression levels, as a first-line therapy for treatment-naïve patients with advanced NSCLC […] Read more


Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in NSCLC

Beth Fand Incollingo
on: January 27, 2021In: Immuno-Biology
Co-mutations in DNA Damage-Response Pathways May Predict Effectiveness of Checkpoint Inhibitors in
            NSCLC

NSCLC that harbors more than one DNA damage-response (DDR) gene alteration is more likely to respond to immunotherapy than disease that harbors one or no such mutations. So concluded investigators […] Read more

Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors

on: January 26, 2021In: Immuno-Biology, WCLC 2020 Archive
Translating Early Research to Adapt CAR T-Cell Therapy to Solid Tumors

Although the initial research into adoptive T-cell therapy for solid tumors was related to tumor-infiltrating lymphocytes, there is a growing interest in the use of adoptive T-cell therapy for the […] Read more

IASLC Logo
ILCN Editorial Group    IASLC.org   

Advertise with Us   

© 2023 IASLC. All Rights Reserved. Powered By TriStar Event Media, LLC   Privacy Policy